Dan Rhodes is Vice President of Oncology Strategy for Thermo Fisher Scientific and adjunct assistant professor at the University of Michigan Center for Translational Pathology. At Thermo Fisher, he led the development of the Oncomine next-generation sequencing assays, which power the National Cancer Institute’s MATCH clinical trial and are the basis for companion diagnostic development programs with pharmaceutical companies.
Previously, Dan was founder and CEO of Compendia Bioscience, the world leader in cancer genomics and bioinformatics, which after six consecutive years of growth, was acquired by Life Technologies. Dan led the development of Compendia’s cancer genome data-mining platform, Oncomine, which has been used by 10,000’s of researchers worldwide and licensed by most pharmaceutical companies. He has co-authored 40 publications and is a co-inventor on 10 patents, most notably, the discovery of gene fusions as the genetic driver of prostate cancer. Dan serves on the oversight committee for MTRAC, on the Advisory Board for the Michigan ELab, and as a finalist judge for the Accelerate Michigan business plan competition. Dan received a Bachelor of Science in Molecular Biology and a Doctorate in Bioinformatics from The University of Michigan.
